1. GPCR/G Protein
  2. Vasopressin Receptor
  3. Mozavaptan

Mozavaptan (Synonyms: OPC-31260)

目录号: HY-18346 纯度: 99.89%

Mozavaptan (OPC-31260) 是一种 benzazepine 衍生物,也是一种有效,选择性,竞争性和口服活性的加压素 V2 受体拮抗剂,IC50 为 14 nM。Mozavaptan 对 V2 受体的选择性比 V1 受体 (IC50 为 1.2 μM) 高约 85 倍,并且可以在体内拮抗精氨酸加压素的抗利尿作用。Mozavaptan 可用于低钠血症,抗利尿激素不适当综合征 (SIADH) 和充血性心力衰竭的研究。

MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务

Mozavaptan Chemical Structure

Mozavaptan Chemical Structure

CAS No. : 137975-06-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内


3.  试用装只面向终端客户

Size Price Stock Quantity
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥660 In-stock
10 mg ¥600 In-stock
50 mg ¥2600 In-stock
100 mg ¥4600 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Mozavaptan:

Top Publications Citing Use of Products
  • 生物活性

  • 纯度 & 产品资料

  • 参考文献


Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment[1][2].

IC50 & Target

IC50: 14 nM (Vasopressin V2 receptor); 1.2 μM (Vasopressin V1 receptor)[1]

In Vitro

Mozavaptan (OPC-31260) inhibits AVP binding to binding to rat liver (V1 receptor) and kidney (V2 receptor) plasma membranes in a competitive manner and that it is about 100 times more selective for V2 receptors. Kd value for [3H]-AVP in rat liver is 1.1 nM; in rat kidney is 1.38 nM. The Kd of [3H]-AVP is reduced significantly in both rat liver and kidney in the presence of Mozavaptan (Kd of 2.47 nM and 5.51 nM for V1 receptor at the doses of 0.3 μM and 1 μM.respectively; Kd of 2.4 nM and 4.03 nM for V2 receptor at the doses of 0.3 μM and 1 μM.respectively)[1].

In Vivo

Mozavaptan (OPC-31260; 1-30 mg/kg; oral administration; hydrated conscious rats) treatment dose-dependently increases urine flow and decreased urine osmolality[1].
Mozavaptan (OPC-31260; 10-100 μg/kg; intravenous injection; male Sprague-Dawley rats) treatment inhibits the antidiuretic action of exogenously administered arginine vasopressin (AVP) in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner[1].

Animal Model: Hydrated conscious rats (300-350 g)[1]
Dosage: 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration: Oral administration
Result: Dose-dependently increased urine flow and decreased urine osmolality.
Molecular Weight









Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 6.2 mg/mL (14.50 mM; Need warming)

H2O : < 0.1 mg/mL (insoluble)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3390 mL 11.6948 mL 23.3896 mL
5 mM 0.4678 mL 2.3390 mL 4.6779 mL
10 mM 0.2339 mL 1.1695 mL 2.3390 mL

储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。 -80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。


Purity: 99.89%

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


MozavaptanOPC-31260OPC31260OPC 31260Vasopressin ReceptorNonpeptideargininevasopressin-V2diureticAVPbenzazepinehydrochlorideSIADHhyponatremiaInhibitorinhibitorinhibit


Your information is safe with us. * Required Fields.



* 需求量:

* 客户姓名:


* Email:

* 电话:


* 公司或机构名称:


Bulk Inquiry

Inquiry Information